Table 2.
Serum and urine parameters at baseline and after at least 12 mo of follow-up
| Parameter | Group A |
Group B |
||
|---|---|---|---|---|
| Baseline | Follow-up Evaluation | Baseline | Follow-up Evaluation | |
| Serum | ||||
| creatinine clearance (ml/min) | 123 ± 41 | 134 ± 56 | 126 ± 14 | 128 ± 36 |
| calcium (mg/dl) | 9.08 ± 0.31 | 9.21 ± 0.40 | 9.32 ± 0.24 | 9.29 ± 0.41 |
| phosphorus (mg/dl) | 2.75 ± 0.33 | 3.49 ± 0.22b | 2.93 ± 0.38 | 2.85 ± 0.43 |
| magnesium (mmol/L) | 0.88 ± 0.09 | 0.91 ± 0.11 | 0.86 ± 0.12 | 0.89 ± 0.14 |
| potassium (mEq/L) | 3.50 ± 0.32 | 4.29 ± 0.39b | 3.42 ± 0.49 | 3.64 ± 0.29 |
| chloride (mEq/L) | 105 ± 4 | 102 ± 3b | 106 ± 4 | 104 ± 5 |
| osmolarity (mOsm/L) | 281 ± 9 | 286 ± 10 | 284 ± 9 | 285 ± 8 |
| PTH (pmol/L) | 4.13 ± 1.98 | 4.07 ± 1.77 | 4.48 ± 1.66 | 4.67 ± 1.90 |
| 25(OH)D3 (nmol/L) | 73.4 ± 17.3 | 71.0 ± 13.2 | 69.4 ± 23.7 | 73.0 ± 19.1 |
| 24-h urine | ||||
| volume (ml) | 2150 ± 231 | 2319 ± 401b | 1950 ± 279 | 2245 ± 251a |
| calcium (mg) | 359 ± 110 | 192 ± 97d | 333 ± 98 | 311 ± 76 |
| phosphorus (mg) | 975 ± 61 | 706 ± 78d | 1023 ± 84 | 893 ± 68c |
| calcium/creatinine (mg/mg) | 0.23 ± 0.15 | 0.15 ± 0.10d | 0.24 ± 0.17 | 0.21 ± 0.13 |
| sodium (mEq) | 212 ± 49 | 177 ± 65d | 207 ± 53 | 165 ± 71 |
| potassium (mEq) | 63 ± 24 | 89 ± 28d | 66 ± 28 | 75 ± 21 |
| chloride (mEq) | 158 ± 69 | 164 ± 57 | 163 ± 58 | 168 ± 44 |
| Na/K | 3.41 ± 0.64 | 2.13 ± 0.55d | 3.19 ± 0.56 | 2.29 ± 0.41d |
| pH | 6.44 ± 0.33 | 6.91 ± 0.52d | 6.23 ± 0.39 | 6.31 ± 0.30 |
| anion gap (mEq/L) | +55 ± 19 | +43 ± 22c | +57 ± 18 | +35 ± 21a |
| citrate (mg) | 288 ± 65 | 553 ± 44d | 267 ± 55 | 287 ± 39 |
| oxalate (mg) | 41 ± 23 | 35 ± 12 | 39 ± 26 | 38 ± 23 |
Data are mean ± SD. Group A, patients who had MSK with PSRF and were on citrate; group B, patients who had MSK with PSRF and were not on citrate.
Statistical significance versus the respective baseline (aP < 0.05, bP < 0.005, cP < 0.001, dP = 0.000).